肿瘤免疫治疗新药研发及生物标记物研究

由于免疫学和肿瘤学发展的不断深入以及交叉渗透,肿瘤免疫学渐渐成为肿瘤治疗的新热点,为肿瘤治疗带来了新的希望。肿瘤免疫疗法主要是通过激活或正常化机体免疫系统,例如T细胞,NK细胞等,对肿瘤细胞进行杀伤,以期达到缓解或治愈的目的。随着肿瘤免疫研究的不断深入,多种肿瘤免疫新药已成功获批,并展现出了前所未有的多癌种普适性,但提高患者响应率仍是肿瘤免疫治疗领域之重要议题。从肿瘤免疫新靶点的研究,联合治疗的探索及生物标记物的应用三个方面浅析肿瘤免疫发展过程中的机遇与挑战。

The Development of Immuno-oncology Therapy and the Biomarker Research

Due to the development of immunology and oncology, and their cross infiltration and integration, immuno-oncology (IO) has gradually become a innovative hot area, which shed new light on cancer therapy. IO therapies fight tumors through activating or normalizing the body’s immune system, such as T cells, NK cells, etc., aiming to achieve disease remission or cure.. Along with the in-depth research, a variety of new IO therapy drugs have been approved and showed the unprecedented universality in a spectrum of cancer types. However, improving patient response rate is still a critical issue in the field. This article will analyze the opportunities and challenges in the process of IO therapy development from the perspectives of new IO target discovery, the combination strategy and the application of biomarkers.